The latest from BioStock
» Biosergen's CEO: "I'm optimistic that we may cure patients"
» Mentice's CEO comments on large order and new platform
» Capital injection from TO 8 strengthens Chordate Medical's investments
» PHI's new CEO: “I am excited to lead us forward with new energy”
» Cereno Scientific CEO on new treatments for rare diseases
Read the newsletter for v.44 here.
See all presentations and panels from BioStock Investing in Life Science - here.
The latest news
Elicera Therapeutics includes first patient in the Phase I/II clinical study CARMA against B-cell lymphoma. Read more.
Xspray decides on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million. Read more.
BBS-Bioactive Bone Substitutes updates on the CE marking process. Read more.
Saniona announces that tesofensine has not yet received approval in Mexico. Read more.
Nanexa announces that all patients have now completed their final visit in the Phase I study of NEX-22 in type 2 diabetes. Read more.
NanoEcho announces that the first study participant has completed the entire study protocol in the dose confirmation study. Read more.
Spermosis announces progress with the second generation JUNO-Checked system. Read more.
Acarix announces that Integrated Delivery Network (IDN) places an order for the Acarix CADScor System. Read more.
Nightingale Health is recruiting Dr. Charles Alessi as Chief Medical Officer. Read more.
Aptahem announces the outcome of the company's rights issue. Read more.
Magnasense carries out previously announced directed new share issue to Atlas Special Opportunities. Read more.
CLS announces that a new board member is purchasing shares in the company and that the CEO and EVP Operations are increasing their shareholdings. Read more.
Navamedic launches Eroxon in Finland. Read more.
Diamyd Medical includes collaboration with INNODIA for increased awareness of type 1 diabetes and for patient recruitment for the phase III study DIAGNODE-3. Read more.
AstraZeneca chooses not to comment on media reports about insurance fraud in China. Read more.
Peptonic Medical announces that the exercise period for warrants of series TO5 begins today. Read more.
Attana publishes a prospectus in connection with an upcoming rights issue. Read more.
Reports
Ambea Bio-Works EQL Pharma Medivir Ultimovac Stenocare Spago Nanomedical Senzime
Congress presentations
Active Biotech Alligator Bioscience Cantargia Diamyd Medical Genmab Mendus Novo Nordisk
Communiqués
Invitations & Announcements
ArcticZymes Technologies BergenBio BioArctic Diamyd Medical Egetis Therapeutics Nanexa Scandion Oncology
This morning's price development
Index: OMXS30 +1,39% Healthcare + 1,37 %
| Winner | Förlorare |
| Sperm count +114,8% | BBS-Bioactive -64,5% |
| Monivent +28,4% | Saniona −39,7% |
| PHI +14,69% | Carbiotix −28% |
| Moberg Pharma +11,7% | ArcticZymes −16,1% |
| Attana +12,9% | SUFFERED −15,9% |